Circulating MicroRNAs in Cancer: Origin, Function and Application

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2012 May 2

PMID 22546315

Citations 95

Authors

Ruimin Ma

Tao Jiang

Xixiong Kang

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the posttranscriptional level. The dysregulation of miRNAs has been linked to a series of diseases, including various types of cancer. Since their discovery in the circulation of cancer patients, there has been a steady increase in the study of circulating miRNAs as stable, non-invasive biomarkers. However, the origin and function of circulating miRNAs has not been systematically elucidated. In this review, we summarize the discovery of circulating miRNAs and their potential as biomarkers. We further emphasize their possible origin and function. Finally, we discuss the application and existing questions surrounding circulating miRNAs in cancer diagnostics. Although several challenges remain to be concerned, circulating miRNAs could be useful, non-invasive biomarkers for cancer diagnosis.

Citing Articles

MicroRNAs in thyroid cancer with focus on medullary thyroid carcinoma: potential therapeutic targets and diagnostic/prognostic markers and web based tools.

Shakiba E, Boroomand S, Kheradmand Kia S, Hedayati M Oncol Res. 2024; 32(6):1011-1019.

PMID: 38827323 PMC: 11136686. DOI: 10.32604/or.2024.049235.

HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis.

Di Agostino S, Canu V, Donzelli S, Pulito C, Sacconi A, Ganci F Cell Death Dis. 2023; 14(8):535.

PMID: 37598177 PMC: 10439938. DOI: 10.1038/s41419-023-06064-9.

Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer.

Bararia A, Chakraborty P, Roy P, Chattopadhay B, Das A, Chatterjee A World J Gastroenterol. 2023; 29(15):2241-2260.

PMID: 37124888 PMC: 10134423. DOI: 10.3748/wjg.v29.i15.2241.

Nutriepigenomics in Environmental-Associated Oxidative Stress.

Rubio K, Hernandez-Cruz E, Rogel-Ayala D, Sarvari P, Isidoro C, Barreto G Antioxidants (Basel). 2023; 12(3).

PMID: 36979019 PMC: 10045733. DOI: 10.3390/antiox12030771.

miRNAs and arsenic-induced carcinogenesis.

Nail A, Ferragut Cardoso A, Montero L, States J Adv Pharmacol. 2023; 96:203-240.

PMID: 36858773 PMC: 10184182. DOI: 10.1016/bs.apha.2022.10.002.

References

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

Chim S, Shing T, Hung E, Leung T, Lau T, Chiu R . Detection and characterization of placental microRNAs in maternal plasma. Clin Chem. 2008; 54(3):482-90. DOI: 10.1373/clinchem.2007.097972. View

Turchinovich A, Weiz L, Langheinz A, Burwinkel B . Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011; 39(16):7223-33. PMC: 3167594. DOI: 10.1093/nar/gkr254. View

Bianchi F, Nicassio F, Marzi M, Belloni E, DallOlio V, Bernard L . A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011; 3(8):495-503. PMC: 3377091. DOI: 10.1002/emmm.201100154. View

Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F . Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder. BJU Int. 1999; 84(6):706-13. DOI: 10.1046/j.1464-410x.1999.00254.x. View

Iguchi H, Kosaka N, Ochiya T . Versatile applications of microRNA in anti-cancer drug discovery: from therapeutics to biomarkers. Curr Drug Discov Technol. 2010; 7(2):95-105. DOI: 10.2174/157016310793180648. View

Zhang H, Yang L, Zhu Y, Yao X, Zhang S, Dai B . Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2010; 71(3):326-31. DOI: 10.1002/pros.21246. View

Sheedy F, Palsson-McDermott E, Hennessy E, Martin C, OLeary J, Ruan Q . Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2009; 11(2):141-7. DOI: 10.1038/ni.1828. View

10.

Kosaka N, Iguchi H, Ochiya T . Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101(10):2087-92. PMC: 11159200. DOI: 10.1111/j.1349-7006.2010.01650.x. View

11.

Park N, Zhou H, Elashoff D, Henson B, Kastratovic D, Abemayor E . Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009; 15(17):5473-7. PMC: 2752355. DOI: 10.1158/1078-0432.CCR-09-0736. View

12.

Lu L, Boldin M, Chaudhry A, Lin L, Taganov K, Hanada T . Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010; 142(6):914-29. PMC: 3049116. DOI: 10.1016/j.cell.2010.08.012. View

13.

Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q . Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol. 2011; 2011:597145. PMC: 3118289. DOI: 10.1155/2011/597145. View

14.

Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L . Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007; 67(7):2912-5. DOI: 10.1158/0008-5472.CAN-07-0520. View

15.

Kim S, Lechman E, Bianco N, Menon R, Keravala A, Nash J . Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol. 2005; 174(10):6440-8. DOI: 10.4049/jimmunol.174.10.6440. View

16.

Urbich C, Kuehbacher A, Dimmeler S . Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008; 79(4):581-8. DOI: 10.1093/cvr/cvn156. View

17.

Reinhart B, Slack F, Basson M, Pasquinelli A, Bettinger J, Rougvie A . The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403(6772):901-6. DOI: 10.1038/35002607. View

18.

Peter M . Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle. 2009; 8(6):843-52. PMC: 2688687. DOI: 10.4161/cc.8.6.7907. View

19.

Okada H, Kohanbash G, Zhu X, Kastenhuber E, Hoji A, Ueda R . Immunotherapeutic approaches for glioma. Crit Rev Immunol. 2009; 29(1):1-42. PMC: 2713019. DOI: 10.1615/critrevimmunol.v29.i1.10. View

20.

Le M, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V . MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009; 23(7):862-76. PMC: 2666337. DOI: 10.1101/gad.1767609. View